OWEN MUMFORD LTD

Founded in Oxford in 1952, Owen Mumford has grown from a small, family-run business to a medical device innovator.

This year, the company is celebrating its 70th anniversary as a global leader in medical device design and manufacture, leading innovation and delivering medical device solutions that respond to customer and market needs.

Through this well-established network it delivers the highest levels of safety, comfort and accuracy in the treatment and diagnosis of chronic diseases such as rheumatoid arthritis, diabetes and multiple sclerosis.

Owen Mumford has pioneered a number of world firsts including an

Oxford Biomedica plc

This Oxford University spin-out, which became a household name after becoming one of the manufacturers of Britain’s Oxford AstraZeneca Covid vaccine, has a lot more strings to its bow as a leading cell and gene therapy group.

Its Oxford-based manufacturing facility, Oxbox, was originally built to solely service the Group’s growing demand for lentiviral vectors in the fast-growing cell and gene therapy market where it is a leading global specialist working with multiple partners. The Oxbox facility was completed at the end of 2019 with automatic lancing device for home blood glucose monitoring and the first plastic auto-injector. Today, the company continues to develop innovative medical device solutions including its Unifine SafeControl safety pen needle and Aidaptus, a two-step single use auto-injector. the Group expecting to have one or potentially two of the manufacturing suites approved during 2020. In April that year the Group joined the Oxford Vaccine Consortium and shortly afterwards signed the first of two agreements with AstraZeneca for Covid-19 vaccine production.

This March the company completed its deal with Homology Medicines Inc, a genetic medicines company listed on the New York-based NASDAQ, to establish Oxford Biomedica Solutions LLC, a new US-based full scope, adeno-associated virus manufacturing and innovation business.